statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (Merrimack or the Company) today announced that it has received a $225 million payment which was due from Ipsen, S.A. as a result of its receipt of...

Merrimack Receives $225 Million Milestone Payment from Ipsen

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK  Get Free Report) was the target of a significant decline in short interest in the month of February. As of February 29th, there was short interest...

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Sees Large Drop in Short Interest

This is a signal that MACK's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Merrimack Pharmaceuticals (MACK, $14.72) RSI Indicator left the overbought zone on March 08, 2024

Merrimack Pharmaceuticals (MACK, $14.77) RSI Indicator left the overbought zone on March 07, 2024

This price move could be a signal that MACK may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...

Merrimack Pharmaceuticals (MACK, $14.77) price may drop as it broke higher Bollinger Band on Mar 07, 2024

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (Merrimack or the Company) today announced its full year 2023 financial results for the period ended December 31, 2023. As Ipsen reported in February...

Merrimack Reports Full Year 2023 Financial Results

Merrimack Pharmaceuticals (MACK, $14.7) RSI Indicator left the overbought zone on March 04, 2024

Wittenberg Investment Management Inc. grew its position in Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK  Free Report) by 2.3% in the 3rd quarter, according to its most recent filing with the...

Wittenberg Investment Management Inc. Buys 4,745 Shares of Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK)

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (Merrimack or the Company) reported that Ipsen, SA (Ipsen) issued a press release today announcing the U.S. Food and Drug Administration has approved...

Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Merrimack Pharmaceuticals (MACK, $14) RSI Indicator left the overbought zone on February 12, 2024

Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA.

Volume	55,162.00
52-Wk High	$15.89
52-Wk Low	$11.53

MACK Merrimack Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals